Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties

Despina Laimou, Theodora Katsila, John Matsoukas, Andrew V Schally, Kostas Gkountelias, George Liapakis, Constantin Tamvakopoulos, Theodore Tselios

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This article describes the rational design, synthesis and pharmacological properties of amide-linked cyclic analogues of Luteinizing Hormone-Releasing Hormone (LHRH) with substitutions at positions 1 (Pro), 6 (d-Leu/d-Trp), 9 (Aze) and 10 (BABA/Acp). These LHRH analogues fulfil the conformational requirements that are known in the literature (bend in the 5-8 segment) to be essential for receptor recognition and activation. Although, they are characterised by an overall low binding affinity to the LHRH-I receptor, the cyclic analogues that were studied and especially the cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH, exhibit a profoundly enhanced in vitro and in vivo stability and improved pharmacokinetics in comparison with their linear counterpart and leuprolide. Upon receptor binding, cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH causes testosterone release in C57/B16 mice (in vivo efficacy) that is comparable to that of leuprolide. Testosterone release is an acutely dose dependent effect that is blocked by the LHRH-I receptor antagonist, cetrorelix. The pharmacokinetic advantages and efficacy of cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH render this analogue a promising platform for future rational drug design studies towards the development of non-peptide LHRH mimetics.

Original languageEnglish
Pages (from-to)237-247
Number of pages11
JournalEuropean Journal of Medicinal Chemistry
Volume58
DOIs
StatePublished - Dec 1 2012

Fingerprint

Gonadotropin-Releasing Hormone
Leuprolide
LHRH Receptors
Pharmacokinetics
Testosterone
Drug Design
Amides
Pharmacology
Substitution reactions
Chemical activation
Pharmaceutical Preparations

Keywords

  • Amide linked cyclization
  • Cyclic peptide analogues
  • Hormone dependent cancer
  • Luteinizing hormone-releasing hormone
  • Medicinal chemistry

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Rationally designed cyclic analogues of luteinizing hormone-releasing hormone : Enhanced enzymatic stability and biological properties. / Laimou, Despina; Katsila, Theodora; Matsoukas, John; Schally, Andrew V; Gkountelias, Kostas; Liapakis, George; Tamvakopoulos, Constantin; Tselios, Theodore.

In: European Journal of Medicinal Chemistry, Vol. 58, 01.12.2012, p. 237-247.

Research output: Contribution to journalArticle

Laimou, Despina ; Katsila, Theodora ; Matsoukas, John ; Schally, Andrew V ; Gkountelias, Kostas ; Liapakis, George ; Tamvakopoulos, Constantin ; Tselios, Theodore. / Rationally designed cyclic analogues of luteinizing hormone-releasing hormone : Enhanced enzymatic stability and biological properties. In: European Journal of Medicinal Chemistry. 2012 ; Vol. 58. pp. 237-247.
@article{79cd922b32464e65be06e6f6fbb58223,
title = "Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties",
abstract = "This article describes the rational design, synthesis and pharmacological properties of amide-linked cyclic analogues of Luteinizing Hormone-Releasing Hormone (LHRH) with substitutions at positions 1 (Pro), 6 (d-Leu/d-Trp), 9 (Aze) and 10 (BABA/Acp). These LHRH analogues fulfil the conformational requirements that are known in the literature (bend in the 5-8 segment) to be essential for receptor recognition and activation. Although, they are characterised by an overall low binding affinity to the LHRH-I receptor, the cyclic analogues that were studied and especially the cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH, exhibit a profoundly enhanced in vitro and in vivo stability and improved pharmacokinetics in comparison with their linear counterpart and leuprolide. Upon receptor binding, cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH causes testosterone release in C57/B16 mice (in vivo efficacy) that is comparable to that of leuprolide. Testosterone release is an acutely dose dependent effect that is blocked by the LHRH-I receptor antagonist, cetrorelix. The pharmacokinetic advantages and efficacy of cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH render this analogue a promising platform for future rational drug design studies towards the development of non-peptide LHRH mimetics.",
keywords = "Amide linked cyclization, Cyclic peptide analogues, Hormone dependent cancer, Luteinizing hormone-releasing hormone, Medicinal chemistry",
author = "Despina Laimou and Theodora Katsila and John Matsoukas and Schally, {Andrew V} and Kostas Gkountelias and George Liapakis and Constantin Tamvakopoulos and Theodore Tselios",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.ejmech.2012.09.043",
language = "English",
volume = "58",
pages = "237--247",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Rationally designed cyclic analogues of luteinizing hormone-releasing hormone

T2 - Enhanced enzymatic stability and biological properties

AU - Laimou, Despina

AU - Katsila, Theodora

AU - Matsoukas, John

AU - Schally, Andrew V

AU - Gkountelias, Kostas

AU - Liapakis, George

AU - Tamvakopoulos, Constantin

AU - Tselios, Theodore

PY - 2012/12/1

Y1 - 2012/12/1

N2 - This article describes the rational design, synthesis and pharmacological properties of amide-linked cyclic analogues of Luteinizing Hormone-Releasing Hormone (LHRH) with substitutions at positions 1 (Pro), 6 (d-Leu/d-Trp), 9 (Aze) and 10 (BABA/Acp). These LHRH analogues fulfil the conformational requirements that are known in the literature (bend in the 5-8 segment) to be essential for receptor recognition and activation. Although, they are characterised by an overall low binding affinity to the LHRH-I receptor, the cyclic analogues that were studied and especially the cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH, exhibit a profoundly enhanced in vitro and in vivo stability and improved pharmacokinetics in comparison with their linear counterpart and leuprolide. Upon receptor binding, cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH causes testosterone release in C57/B16 mice (in vivo efficacy) that is comparable to that of leuprolide. Testosterone release is an acutely dose dependent effect that is blocked by the LHRH-I receptor antagonist, cetrorelix. The pharmacokinetic advantages and efficacy of cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH render this analogue a promising platform for future rational drug design studies towards the development of non-peptide LHRH mimetics.

AB - This article describes the rational design, synthesis and pharmacological properties of amide-linked cyclic analogues of Luteinizing Hormone-Releasing Hormone (LHRH) with substitutions at positions 1 (Pro), 6 (d-Leu/d-Trp), 9 (Aze) and 10 (BABA/Acp). These LHRH analogues fulfil the conformational requirements that are known in the literature (bend in the 5-8 segment) to be essential for receptor recognition and activation. Although, they are characterised by an overall low binding affinity to the LHRH-I receptor, the cyclic analogues that were studied and especially the cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH, exhibit a profoundly enhanced in vitro and in vivo stability and improved pharmacokinetics in comparison with their linear counterpart and leuprolide. Upon receptor binding, cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH causes testosterone release in C57/B16 mice (in vivo efficacy) that is comparable to that of leuprolide. Testosterone release is an acutely dose dependent effect that is blocked by the LHRH-I receptor antagonist, cetrorelix. The pharmacokinetic advantages and efficacy of cyclo(1-10)[Pro1, d-Leu6, BABA10] LHRH render this analogue a promising platform for future rational drug design studies towards the development of non-peptide LHRH mimetics.

KW - Amide linked cyclization

KW - Cyclic peptide analogues

KW - Hormone dependent cancer

KW - Luteinizing hormone-releasing hormone

KW - Medicinal chemistry

UR - http://www.scopus.com/inward/record.url?scp=84868261962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868261962&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2012.09.043

DO - 10.1016/j.ejmech.2012.09.043

M3 - Article

C2 - 23127987

AN - SCOPUS:84868261962

VL - 58

SP - 237

EP - 247

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -